Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by DeathXray33on Feb 09, 2024 7:15am
163 Views
Post# 35871795

RE:RE:RE:RE:RE:RE:RE:New Press Release - Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

RE:RE:RE:RE:RE:RE:RE:New Press Release - Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
enriquesuave wrote:

A new investor like us longs should think, that this MC is way too low given our accomplishments.  Compared to peers such as CGON, $2.6 Billion US,  IBRX, $ 2 Billion US, we could go up 50-100 times to catch up in MC value.  Short term catalysts are BTD, more data, Licensing agreements with Big Pharma. More preclinical data on GBM or NSCLC for XPDT which in of itself is a potential wirth of many Billions.  At $30 million MC vs $2-3 Billion one could think and hope that once BTD is granted, everyone will take TLT seriously.  All IMHO 


beenthere wrote: That's great but it's coming from an investor who has been here for years and knows much about TLT.

What would you think what a new investor  who would know very little about TLT think after reading this news? Would they be interested and dig deeper or think 3 years in the making .. maybe. I think I will pass!  At best  I might add it to my watch list.

 



Take the G out of CGON. LOL...
<< Previous
Bullboard Posts
Next >>